741 related articles for article (PubMed ID: 15847795)
1. Complexes between C1q and C3 or C4: novel and specific markers for classical complement pathway activation.
Wouters D; Wiessenberg HD; Hart M; Bruins P; Voskuyl A; Daha MR; Hack CE
J Immunol Methods; 2005 Mar; 298(1-2):35-45. PubMed ID: 15847795
[TBL] [Abstract][Full Text] [Related]
2. Studies on the haemolytic activity of circulating C1q-C3/C4 complexes.
Wouters D; Brouwer MC; Daha MR; Hack CE
Mol Immunol; 2008 Apr; 45(7):1893-9. PubMed ID: 18054386
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of classical complement pathway activation in rheumatoid arthritis: measurement of C1q-C4 complexes as novel activation products.
Wouters D; Voskuyl AE; Molenaar ET; Dijkmans BA; Hack CE
Arthritis Rheum; 2006 Apr; 54(4):1143-50. PubMed ID: 16572449
[TBL] [Abstract][Full Text] [Related]
4. Activation of classical pathway complement in chronic inflammation. Elevated levels of circulating C3d and C4d split products in rheumatoid arthritis and Crohn's disease.
Petersen NE; Elmgreen J; Teisner B; Svehag SE
Acta Med Scand; 1988; 223(6):557-60. PubMed ID: 3389208
[TBL] [Abstract][Full Text] [Related]
5. Human astrovirus coat protein binds C1q and MBL and inhibits the classical and lectin pathways of complement activation.
Hair PS; Gronemus JQ; Crawford KB; Salvi VP; Cunnion KM; Thielens NM; Arlaud GJ; Rawal N; Krishna NK
Mol Immunol; 2010 Jan; 47(4):792-8. PubMed ID: 19896716
[TBL] [Abstract][Full Text] [Related]
6. Reflection of disease activity in rheumatoid arthritis by indices of activation of the classical complement pathway.
Makinde VA; Senaldi G; Jawad AS; Berry H; Vergani D
Ann Rheum Dis; 1989 Apr; 48(4):302-6. PubMed ID: 2785367
[TBL] [Abstract][Full Text] [Related]
7. Complement activation and impaired capacity to solubilize immune complexes or to prevent their formation in essential mixed cryoglobulinemia.
Corvetta A; Spaeth PJ; Ghirelli PA; Orecchioni F; Buetler R; Montroni M; Nydegger UE
Diagn Immunol; 1983; 1(4):315-23. PubMed ID: 6333960
[TBL] [Abstract][Full Text] [Related]
8. Significance of complement components C1q and C4 bound to circulating immune complexes in juvenile idiopathic arthritis: support for classical complement pathway activation.
Gilliam BE; Reed MR; Chauhan AK; Dehlendorf AB; Moore TL
Clin Exp Rheumatol; 2011; 29(6):1049-56. PubMed ID: 22153664
[TBL] [Abstract][Full Text] [Related]
9. Heparin-protamine complexes and C-reactive protein induce activation of the classical complement pathway: studies in patients undergoing cardiac surgery and in vitro.
Bruins P; te Velthuis H; Eerenberg-Belmer AJ; Yazdanbakhsh AP; de Beaumont EM; Eijsman L; Trouwborst A; Hack CE
Thromb Haemost; 2000 Aug; 84(2):237-43. PubMed ID: 10959695
[TBL] [Abstract][Full Text] [Related]
10. The complement fixing ability of putative circulating immune complexes in rheumatoid arthritis and its relationship to extra-articular disease.
Bourke BE; Moss IK; Mumford P; Horsfall A; Maini RN
Clin Exp Immunol; 1982 Jun; 48(3):726-32. PubMed ID: 6981475
[TBL] [Abstract][Full Text] [Related]
11. CRP-mediated activation of complement in vivo: assessment by measuring circulating complement-C-reactive protein complexes.
Wolbink GJ; Brouwer MC; Buysmann S; ten Berge IJ; Hack CE
J Immunol; 1996 Jul; 157(1):473-9. PubMed ID: 8683153
[TBL] [Abstract][Full Text] [Related]
12. [Serum complement levels in patients with rheumatoid arthritis and vasculitis].
Tomooka K
Fukuoka Igaku Zasshi; 1989 Oct; 80(10):456-66. PubMed ID: 2613159
[TBL] [Abstract][Full Text] [Related]
13. Prevention of immune precipitation by purified classical pathway complement components.
Naama JK; Hamilton AO; Yeung-Laiwah AC; Whaley K
Clin Exp Immunol; 1984 Nov; 58(2):486-92. PubMed ID: 6333948
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of C3 deposition on solid-phase bound immune complexes by lactoferrin.
Kievits F; Kijlstra A
Immunology; 1985 Mar; 54(3):449-56. PubMed ID: 3844370
[TBL] [Abstract][Full Text] [Related]
15. Classical pathway of complement activation in mammalian kidneys.
Zwirner J; Felber E; Burger R; Bitter-Suermann D; Riethmüller G; Feucht HE
Immunology; 1993 Oct; 80(2):162-7. PubMed ID: 8262545
[TBL] [Abstract][Full Text] [Related]
16. Specific inhibition of the classical complement pathway with an engineered single-chain Fv to C1q globular heads decreases complement activation by apoptotic cells.
Duvall MR; Hwang HY; Boackle RJ
Immunobiology; 2010 May; 215(5):395-405. PubMed ID: 19586684
[TBL] [Abstract][Full Text] [Related]
17. A novel ELISA for the assessment of classical pathway of complement activation in vivo by measurement of C4-C3 complexes.
Zwirner J; Dobos G; Götze O
J Immunol Methods; 1995 Oct; 186(1):55-63. PubMed ID: 7561148
[TBL] [Abstract][Full Text] [Related]
18. C1 subcomponent complexes: basic and clinical aspects.
Laurell AB; Sjöholm AG
Behring Inst Mitt; 1993 Dec; (93):292-8. PubMed ID: 8172579
[TBL] [Abstract][Full Text] [Related]
19. Activation of the complement system in normal pregnancy and preeclampsia.
Derzsy Z; Prohászka Z; Rigó J; Füst G; Molvarec A
Mol Immunol; 2010 Apr; 47(7-8):1500-6. PubMed ID: 20181396
[TBL] [Abstract][Full Text] [Related]
20. Direct binding of C1q to apoptotic cells and cell blebs induces complement activation.
Nauta AJ; Trouw LA; Daha MR; Tijsma O; Nieuwland R; Schwaeble WJ; Gingras AR; Mantovani A; Hack EC; Roos A
Eur J Immunol; 2002 Jun; 32(6):1726-36. PubMed ID: 12115656
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
